Anurag S. Rathore

Most analytical approaches used for the determination of low-molecular-weight noncovalent aggregates in protein pharmaceuticals suffer from important limitations. This first part of this two-part column series discusses those limitations.

In this installment, we discuss fluorescence-detection size exclusion chromatography (FSEC) technology and its implications in protein characterization, specifically the development and characterization of biologics.  

Fluorescence-detection size-exclusion chromatography and its implications in protein characterization, specifically the development and characterization of biologics, is reviewed.

In this article, we discuss the role of the gradient in protein separations by reversed-phase and ionexchange high performance liquid chromatography (HPLC).

A discussion of the role of the gradient in separation by reversed-phase and ion-exchange HPLC, with data from two products to illustrate the key points

Isranalytica offered great talks on biotechnology, on topics from comprehensive protein characterization to middle-out proteomics to capillary electrophoresis for glycoprofiling.

An overview of high-throughput process development (HTPD) tools and approaches, as well as a case study

Glycoproteins appear to have become the most common biopharmaceutical product today, and they also seem to be increasing in popularity and importance with time.

The authors provide an introduction to the topic of biosimilars, review the available regulatory guidance, and discuss the various scientific challenges that are present.

In the first installment of LCGC's newest column, the authors address the topic of analytical biotechnology.

The author presents an approach to screen resins for chromatographic optimization in the purification process of a protein drug substance.